Mastocytosis

Advances in Dermatology

Volumn 19, Issue , 2003, Pages 207-236

  Tharp, Michael D ^a   Chan, I Ja ^a   Paller, Amy S ^b,c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CETIRIZINE; CIMETIDINE; CODEINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DIMETHYLTUBOCURARINE CHLORIDE; DIPHENHYDRAMINE; DOXEPIN; ENFLURANE; ETOMIDATE; FAMOTIDINE; FEXOFENADINE; ISOFLURANE; KETOTIFEN; LIDOCAINE; LORATADINE; MORPHINE; NIZATIDINE; PREDNISONE; PSORALEN; RANITIDINE; SUXAMETHONIUM; THIOPENTAL; TUBOCURARINE CHLORIDE;

APOPTOSIS; BONE MARROW; CARDIOPULMONARY INSUFFICIENCY; CELL MATURATION; CHILDHOOD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HYPOTHYROIDISM; LIVER FUNCTION TEST; LYMPH NODE; MAST CELL; MASTOCYTOSIS; NEUROLOGIC DISEASE; OSTEOLYSIS; OSTEOPOROSIS; PROGNOSIS; PSYCHOLOGICAL ASPECT; REVIEW; SKIN BIOPSY; SKIN DEFECT; SKIN DISEASE; SPLEEN; SURVIVAL; THROMBOCYTOPENIA; URINALYSIS; X RAY; ADULT; CHILD; URTICARIA PIGMENTOSA;

ADULT; CHILD; HUMANS; MASTOCYTOSIS, CUTANEOUS;

EID: 0642368048     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (123)

1. Nettleship E, Tay W: Rare forms of urticaria. Br Med J 2:323-324, 1869.
2. Tharp MD, Longley JL Jr: Mastocytosis. Dermatol Clin 19:679-691, 2001.
3. Kettelhut BV, Metcalfe DD: Pediatric mastocytosis. J Invest Dermatol 96:15S-18S, 1991.
4. Caplan RM: The natural course of urticaria pigmentosa. Arch Dermatol 87:146-157, 1963.
5. Shaw JM: Genetic aspects of urticaria pigmentosa. Arch Dermatol 97:137-138, 1968.
6. Hartmann K, Bruns S, Henz B: Mastocytosis: Review of clinical and experimental aspects. J Invest Dermatol 6:143-147, 2001.
7. Longley BJ, Metcalfe DD, Tharp MD, et al: Activating and dominant inactivating c-kit catalytic domain mutations indistinct forms of human mastocytosis. Proc Natl Acad Sci USA 96:1609-1614, 1999.
8. Rockoff VS: Urticaria pigmentosa in identical twins. Arch Dermatol 114:1227-1228, 1978.
9. Selmanowitz VJ, Orentreich NO: A clinical genetic evaluation. J Heredity 61:91-94, 1970.
10. Selmanowitz VJ, Orentreich NO, Tiango CC: Uniovular twins discordant for cutaneous mastocytosis. Arch Dermatol 102:34-41, 1970.
11. Chang A, Tung R, Schlesinger T, et al: Familial cutaneous mastocytosis. Pediatr Dermatol 18:271-276, 2001.
12. Kettlehut BV, Parker RI, Travis WD, et al: Hematopathology of the bone marrow in pediatric cutaneous mastocytosis. J Clin Pathol 91:558-562, 1989.
13. Sagher F, Even-Paz: Mastocytosis and the Mast Cell. Chicago, Year Book Medical Publishers, 1967, pp 10-291.
14. Travis W, Li C-Y, Bergstrahl E, et al: Systemic mast cell disease. Medicine 67:345-368, 1988.
15. Webb T, Li C-Y, Yam L: Systemic mast cell disease: A clinical and hematopathologic study of 26 cases. Cancer 49:927-938, 1982.
16. Murphy M, Walsh DJ, Drumm B, et al: Bullous mastocytosis: A fatal outcome. Pediatr Dermatol 6:452-455, 1999.
17. Sutter MC, Beaulieu G, Birt AR: Histamine liberation by codeine and polymyxin B in urticaria pigmentosa. Arch Dermatol 86:217-221, 1962.
18. Hartmann K, Henz BM: Cutaneous mastocytosis - clinical heterogeneity. Int Arch Allergy Immunol 127:143-146, 2002.
19. Ball FI: Telangiectasis macularis eruptiva perstans: Report of an early stage in a child. Arch Dermatol Syphilol 36:65-69, 1937.
20. Ellis D: Treatment of telangiectasis macularis eruptiva perstans with the 585 nm flashlamp-pumped dye laser. Dermatol Surg 22:33-37, 1996.
21. Gibbs NF, Friedlander SF, Harpster EF: Telangiectasia macularis eruptiva perstans. Pediatr Dermatol 17:194-197, 2000.
22. Chang A, Tung RC, Schlesinger T, et al: Familial cutaneous mastocytosis. Pediatr Dermatol 18:271-276, 2001.
23. Orkin M, Good RA, Clawson CC, et al: Bullous mastocytosis. Arch Dermatol 101:547-562, 1970.
24. Soter NA: The skin in mastocytosis. J Invest Dermatol 96:32S-39S, 1991.
25. Asinoff R, Soter NA, Freedburg I: Solitary mastocytonia in an adult. J Dermatol Surg Oncol 19:487-488, 1993.
26. Tolmach JA: Urticaria pigmentosa - solitary lesion in an adult. Arch Dermatol 86:545, 1962.
27. Griffiths WAD, Daneshbod K: Pseudoxanthomatous mastocytosis. Br J Dermatol 93:91-95, 1975.
28. Meneghini CL, Angelini G: Systemic mastocytosis with the diffuse crocodile-like pachydermic skin, pedunculated pseudofibromas and comedones. Br J Dermatol 103:329-333, 1980.
29. Willemze R, Reither DJ, Scheffer E, et al: Diffuse cutaneous mastocytosis with multiple cutaneous mastocytomas. Br J Dermatol 102:601-607, 1980.
30. Kasper C, Freeman RG, Tharp MD: Diagnosis of mastocytosis subsets using a morphometric point counting technique. Arch Dermatol 123:1017-1021, 1987.
31. Miner PB Jr: The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis. J Invest Dermatol 96:40S-44S, 1991.
32. Schleimer RP, MacGlashan DW, Peters SP, et al: Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Resp Dis 133:614-617, 1986.
33. Mican J, Bisceglie A, Fong T, et al: Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 22:1163-1170, 1995.
34. Baron T, Koehler R, Rodgers W, et al: Mast cell cholangiopathy: Another cause of sclerosing cholangitis. Gastroenterology 109:1677-1681, 1195.
35. Fallon MD, Whyte MP, Teitelbaum SL: Systemic mastocytosis associated with generalized osteopenia. Hum Pathol 12:813-820, 1981.
36. Avioli LV: Heparin-induced osteopenia: An appraisal. Adv Exp Med Biol 52:375-391, 1975.
37. Haney K, Russell W, Raila FA, et al: MRI characteristics of systemic mastocytosis of the lumbosacral spine. Skeletal Radiol 25:171-173, 1996.
38. Ho LM, Lipper MH: Mastocytosis of the axial skeleton presenting as an epidural mass lesion. AJR 167:716-718, 1996.
39. Russell J, Russell S, Trupin K: The effect of histamine on the growth of cultured fibroblasts isolated from normal and keloid tissue. J Clin Physiol 93:389-393, 1977.
40. Gattei v, Aldinucci D, Quinn JM, et al: Human osteoclasts and preosteoclast cells (FLG 29.1) express functional c-kit receptors and interact with osteoblast and stromal cells via membrane-bound stem cell growth factor. Cell Growth Differ 7:753-763, 1996.
41. Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128:344-350, 2002.
42. McKenna MJ: Histomorphometric study of mast cells in normal bone, osteoporosis, and mastocytosis using a new stain. Calcif Tissue Int 55:257-259, 1994.
43. Parker RI: Hematologic aspects of mastocytosis: I: Bone marrow pathology in adult and pediatric systemic mast cell disease. J Invest Dermatol 96:47S-51S, 1991.
44. Andrew SM, Freemont AJ: Skeletal mastocytosis. J Clin Pathol 46:1033-1035, 1993.
45. Linkhart TA, Linkhart SG, MacCharles DC, et al: Interleukin-6 messenger RNA expression and interleukin-6 protein secretion in cells isolated from normal human bone: Regulation by interleukin-1. J Bone Min Res 6:1285-1294, 1991.
46. Li CY, Beak JY: Mastocytosis and fibrosis: Role of cytokines. Int Arch Allergy Immunol 127:123-126, 2002.
47. Escribano L, Diaz-Agustin B, Nunez R, et al: Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Immunol 127:127-132, 2002.
48. Metcalfe DD: The liver, spleen, and lymph nodes in mastocytosis. J Invest Dermatol 96:45S-46S, 1991
49. Travis WD, Li C-Y: Pathology of the lymph node and spleen in systemic mast cell disease. Modern Pathol 1:4-14, 1986.
50. Worobec AS, Semere T, Nagata H, et al: Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 83:2120-2129, 1998.
51. Rogers M, Bloomingdale K, Murawski Benjamin, et al: Mixed organic brain syndrome as a manifestation of systemic mastocytosis. Psychosom Med 48:437-447, 1986.
52. Soter NA, Austen F, Wasserman SI: Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 301:465-469, 1979.
53. Kirshenbaum AS, Goff JP, Kessler SW, et al: Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 148:772-777, 1992.
54. Kirshenbaum AS, Kessler SW, Goff JP, et al: Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 46:1410-1415, 1991.
55. Rottem M, Okada T, Goff JP, et al: Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from DC34+/Fce/RI- cell population. Blood 84:2489-2496, 1994.
56. Anderson DM, Lyman SD, Baird A, et al: Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 63:235-243, 1990.
57. Flanagan JG, Leder P: The c-kit ligand: A cell surface molecule altered in steel mutant fibroblasts. Cell 63:185-194, 1991.
58. Funasaka Y, Boulton T, Cobb M, et al: c-Kit kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell 3:197-209, 1992.
59. Geissler EN, Ryan MA, Housman DE: The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55:185-192, 1988.
60. Lev S, Blechman JM, Givol D, et al: Steel factor and c-kit protooncogene: Genetic lessons in signal transduction. Crit Rev Oncog 5:41-168, 1994.
61. Longley BJ, Tyrell L, Lu SZ, et al: Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 12:312-314, 1996.
62. Nagata H, Worobec AS, Oh CK, et al: Identification of a point mutation in the catalytic domain of the protooncogene c-KIT in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92:10560-10564, 1995.
63. d genotype. In: Galli SJ, Austen KF (eds). Mast Cell and Basophil Differentiation and Function in Health and Disease. New York, Raven Press, 1989, pp 15-25.
64. Costa JJ, Demerti GD, Harrist TJ, et al: Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 183:2681-2686, 1996.
65. Bischoff SC, Sellge G: Mast cell hyperplasia: Role of cytokines. Int Arch Allergy Immunol 127:118-12, 2002.
66. Nagata H, Okada T, Worobec AS, et al: c-Kit mutation in a population of patients with mastocytosis. Int Arch Allergy Immunol 113:184-186, 1997.
67. Feger F, Dumas A, Lerich L, et al: Kit and c-kit mutations in mastocytosis: A short overview with special references to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 127:110-114, 2002.
68. Longley BJ, Tyrrell L, Ma Y, et al: Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci USA 94:9017-9021, 1998.
69. Metcalfe D: Classification and diagnosis of mastocytosis: Current status. J Invest Dermatol 96:2S-4S, 1991.
70. McElroy EA, Phyliky RL, Li CY: Systemic mast cell disease associated with the hypereosinophilic syndrome. Mayo Clin Proc 73:47-50, 1998.
71. Avila NA, Ling A, Worobec AS, et al: Systemic mastocytosis: CT and US features of abdominal manifestations. Radiology 202:367-372, 1997.
72. Fromer JL, Jaffee N: Urticaria pigmentosa and acute lymphoblastic leukemia. Arch Dermatol 107:283-284, 1973.
73. Lishner M, Confino-Cohen R, Mekori YA, et al: Trisomies 9 and 8 detected by fluorescence in situ hybridization in patients with systemic mastocytosis. J Allergy Clin Immunol 98:199-204, 1996.
74. Bain BJ: Systemic mastocytosis and other mast cell neoplasms. Br J Haematol 106:9-17, 1999.
75. Waters WJ, Lacson PS: Mast cell leukemia presenting as urticaria pigmentosa. Pediatrics 19:1033-1042, 1957.
76. Meggs WJ, Friedman MM, Kramer N, et al: Lymphadenopathic mastocytosis with eosinophilia. Clin Res 3:162A, 1985 (abstract).
77. Travis W, Li C-Y, Hoagland H, et al: Mast cell leukemia: Report of a case and review of the literature. Mayo Clin Proc 61:957-966, 1986.
78. Craig SS, Schechter NM, Schwartz LB: Ultrastructural analysis of human T and TC mast cells identified by immunoelectron microscopy. Lab Invest 58:682-691, 1988.
79. Irani AA, Schechter NM, Craig SS, et al: Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A 83:4464-4468, 1986.
80. Weidner N, Austen KF: Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Pathol Res Pract 189:156-162, 1993.
81. Kasper CS, Tharp MD: Quantification of cutaneous mast cells using morphometric point counting and a conjugated avidin stain. J Am Acad Dermatol 16:326-331, 1987.
82. Einhorn S, Strander H: Interferon treatment of human malignancies - a short review. Med Oncol Tumor Pharmacother 10:25-29, 1993.
83. Valent P, Escribano L, Parwaresch RM, et al: Recent advances in mastocytosis research. Int Arch Allergy Immunol 120:1-7, 1999.
84. Schwartz LB, Sakai K, Bradford TR, et al: The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 96:2702-2710, 1995.
85. Kanthawatana S, Carias K, Arnaout R, et al: The potential clinical utility of serum a-protryptase levels. J Allergy Clin Immunol 103:1092-1099, 1999.
86. Brockow K, Akin C, Huber M, et al: Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: Relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol 48:508-516, 2003.
87. Granerus G, Olafasson JH, Roupe G: Studies on histamine metabolism in mastocytosis. J Invest Dermatol 80:410-416, 1983.
88. Keyzer JL, DeMonchy JGR, vanDoormaal JJ, et al: Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med 309:1603-1605, 1983.
89. Feldman J: Histaminuria from histamine-rich foods. Arch Intern Med 143:2099-2102, 1983.
90. Morrow J, Guzo C, Lazarus G, et al: Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol 104:937-940, 1995.
91. Roberts LJ, Sweetman BJ, Lewis RA, et al: Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 303:1400-1404, 1980.
92. Akin C, Metcalfe DD: Surrogate markers of disease in mastocytosis. Int Arch J Allergy Immunol 127:133-136, 2002.
93. Poppel MH, Gruber WF, Silber R, et al: The roentgen manifestations of urticaria pigmentosa (mastocytosis). AJR Am J Roentgenol 82:239-249, 1959.
94. Lucaya J, Perez-Candela V, Celestina A, et al: Mastocytosis with skeletal and gastrointestinal involvement in infancy. Two case reports and a review of the literature. Radiology 131:363-366, 1979
95. Horan RF, Austen KF: Systemic mastocytosis: Retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 96:5S-14S, 1991.
96. Richelson E: Tricyclic antidepressants and H1 receptors. Mayo Clin Proc 54:669-674, 1979.
97. Kors JW, Van Doormal JJ, Breukelman H, et al: Long-term follow-up of indolent mastocytosis in adults. J Intern Med 239:157-164, 1996.
98. Pardanani A, Gbaek JY, Li CY, et al: Systemic mast cell disease without associated hematologic disorder: A combined retrospective and prospective study. Mayo Clin Proc 77:1169-1175, 2002).
99. Casale TB, Bowman S, Kaliner M: Induction of human cutaneous mast cell degranulation by opiates and endogenous peptides: Evidence for opiate and nonopiate receptor participation. J Allergy Clin Immunol 73:775-781, 1984.
100. Moss J, Rosow CE: Histamine release by narcotics and muscle relaxants in humans. Anesthesiology 59:330-339, 1983.
101. Scott HW, Parris WCV, Sandidge PC, et al: Hazards in operative management of patients with systemic mastocytosis. Ann Surg 197:507-514, 1983.
102. Borgeat A, Ruetsch YA: Anesthesia in a patient with malignant systemic mastocytosis using a total intravenous anesthetic technique. Anesth Analg 86:442-444, 1998.
103. 1-receptor antagonists: Clinical pharmacology. Clin Exp Allergy 10:19-24, 1990.
104. 2 receptors in the human peripheral circulation. Br J Pharmacol 56:494-496, 1976.
105. Frieri M, Alling DW, Metcalfe D: Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Am J Med 78:9-14, 1985.
106. Hirschowitz BI, Groake JF: Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis. Ann Intern Med 90:769-771, 1979.
107. Kurosawa M, Amano H, Kanbe N, et al: Heterogeneity of mast cells in mastocytosis and inhibitory effect of ketotifen and ranitidine on indolent systemic mastocytosis. J Allergy Clin Immunol 100:825-832, 1997.
108. Horan RF, Sheffer AL, Austen KF, et al: Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 25:852-855, 1990.
109. Vella-Briffa D, Eady R, James M, et al: Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa. Br J Dermatol 109:67-75, 1983.
110. Kolde G, Frosch P, Czarnetzki B: Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: Histomorphometric, ultrastructural, and biochemical investigations. J Invest Dermatol 83:175-178, 1984.
111. Czarnetzki BM, Rosenbach T, Kolde G, et al: Phototherapy of urticaria pigmentosa: Clinical response and change of cutaneous reactivity, histamine and chemotactic leukotrienes. Arch Dermatol Res 277:105-113, 1985.
112. Godt O, Proksch E, Streit V, et al: Short-and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 195:35-39, 1997.
113. Barton J, Lavker RM, Schechter NM, et al: Treatment of urticaria pigmentosa with corticosteroids. Arch Dermatol 121:1516-1523, 1985.
114. Kurosawa M, Amano H, Kanbe N, et al: Response to cyclosporin and low dose methylprednisone in aggressive systemic mastocytosis. J Allergy Clin Immunol 103:8412-420, 1999.
115. Czarnetzki B, Algermissen B, Jeep S, et al: Interferon treatment of patients with chronic urticaria and mastocytosis. J Am Acad Dermatol 30:500-501, 1994.
116. Worobec A, Kirshenbaum A, Schwartz L, et al: Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 22:501-508, 1996.
117. Butterfield JH: Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 138:489-495, 1998.
118. Pardini S, Bosincu L, Bonfigli S, et al: Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon (letter). Acta Haematol 85:220, 1991.
119. Turk J, Oates JA, Roberts LJ II: Intervention with epinephrine in hypotension associated with mastocytosis. J Allergy Clin Immunol 71:189-192, 1983.
120. Teferi A, Li CY, Butterfield, JH, et al: Treatment of systemic mast cell disease with cladribine. N Engl J Med 344:307-08, 2001.
121. Johnstone PA, Mican JM, Metcalfe DD, et al: Radiotherapy of refractory bone pain due to neutral protease compositions. Proc Natl Acad Sci U S A 83:4464-4468, 1986.
122. Leng MY, Metcalfe DD, Dimitrijevic AC, et al: The c-kit mutations causing human mastocytosis is resistant to STI 571 and other KIT kinase inhibitors: Kinases with enzymatic site mutations show different inhibitory sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741-1744, 2002.
123. Chan I, Kayashima K, Tharp MD: The MAPK and JAK3 signaling pathways in mastocytosis. J Invest Dermatol 119:282, 2002 (abstract).